Metagenomi director buys 20,000 shares

Metagenomi Therapeutics, Inc. (MGX) director Reid Laurence reported open-market purchases of a total of 20,000 shares of common stock on September 9, 2026.

Rhea-AI Filing Summary

Metagenomi Therapeutics, Inc. (MGX) director Reid Laurence reported open-market purchases of a total of 20,000 shares of common stock on September 9, 2026. The purchases included 19,883 shares at a weighted average price of $1.17 per share and 117 shares at $1.18 per share. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 2 txns

Insider Reid Laurence

Role Director

Bought 20,000 shs ($23K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	19,883	$1.17	$23K
Purchase	Common Stock	117	$1.18	$138.06

Holdings After Transaction: Common Stock — 20,000 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

Key Figures

Total shares purchased: 20,000 shares Shares in weighted-average trade: 19,883 shares Weighted average purchase price: $1.17 per share +2 more

5 metrics

Total shares purchased 20,000 shares Common stock bought by director on September 9, 2026

Shares in weighted-average trade 19,883 shares Purchased at weighted average price on September 9, 2026

Weighted average purchase price $1.17 per share For 19,883-share transaction; individual prices $1.165–$1.175

Second trade price $1.18 per share For 117-share purchase on September 9, 2026

Number of purchase transactions 2 transactions Open-market or private purchases of common stock

Key Terms

weighted average price, Rule 10b5-1, open market or private transaction

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for these transactions."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction financial

"Purchase in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MGX director Reid Laurence report on this Form 4?

He reported open-market purchases totaling 20,000 shares of Metagenomi Therapeutics common stock on September 9, 2026, split between two separate transactions.

At what prices did the MGX shares trade in the reported insider purchases?

One transaction for 19,883 shares used a weighted average price of $1.17 per share, with individual trades ranging from $1.165 to $1.175. A second transaction for 117 shares was executed at $1.18 per share.

Were the September 9, 2026 MGX insider purchases under a Rule 10b5-1 plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for these transactions.

What type of security did the MGX insider purchase on September 9, 2026?

The reporting person purchased common stock of Metagenomi Therapeutics, Inc. in open-market or private transactions, as described in the Form 4.

How many separate purchase transactions did MGX report on this Form 4?

The Form 4 shows two separate purchase transactions in Metagenomi Therapeutics common stock on September 9, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 07:52 PM EDT Accepted by SEC EDGAR 09/11/2026 - 07:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reid Laurence

(Last) (First) (Middle)

C/O METAGENOMI THERAPEUTICS, INC.

5959 HORTON STREET, 7TH FLOOR

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Metagenomi Therapeutics, Inc. [ MGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2026		P		19,883	A	$1.17(1)	19,883	D
Common Stock	09/09/2026		P		117	A	$1.18	20,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

	/s/ Matthew L. Wein, attorney-in-fact	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)